Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Download Data

Icosavax Inc Shareholders' Equity for the Trailing 12 Months (TTM) ending September 30, 2023: USD 232.38 M

Icosavax Inc Shareholders' Equity is USD 232.38 M for the Trailing 12 Months (TTM) ending September 30, 2023, a 2.98% change year over year. Shareholders' Equity is the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Icosavax Inc Shareholders' Equity for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 225.66 M, a -22.83% change year over year.
Icosavax Inc Shareholders' Equity for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 292.44 M.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends